Targets › NLRP3
3 programs from 3 companies in 6 trials: 3 Phase 1, 3 Phase 2; Neurology, Metabolic and endocrine, Immunology; next expected readout Dec 2026.
Sensor component of the NLRP3 inflammasome, which mediates inflammasome activation in response to defects in membrane integrity, leading to secretion of inflammatory cytokines IL1B and IL18 and pyroptosis. In response to pathogens and other damage-associated signals that affect the integrity of membranes, initiates the formation of the inflammasome polymeric complex composed of NLRP3, CASP1 and PYCARD/ASC.…. (UniProt, Q96P20)
Open in Phaseline: the race on NLRP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Olatec Therapeutics | Dapansutrile NACHT, LRR and PYD domains-containing protein 3 inhibitor | NLRP3 | Phase 2 | Acute Gout Flare; Parkinson Disease; Diabetes Mellitus, Type 2; Melanoma | Dec 2026 |
| AC Immune | ACI-19764 NLRP3 inflammasome inhibitor | NLRP3 | Phase 1 | Healthy Participants | Dec 2026 |
| Highlightll Pharmaceutical (USA) | HL-400 NLRP3 inflammasome inhibitor | NLRP3 | Phase 1 | Parkinson Disease | – |
Parkinson Disease (2) Acute Gout Flare (1) Diabetes Mellitus, Type 2 (1) Melanoma (1) Healthy Participants (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.